← back to search

Moherndran Archary

King Edward VIII Hospital · ZA
Area of research
Infectious Diseases · Virology
Research interest
Research interests include HIV/AIDS Research and Interventions, HIV/AIDS drug development and treatment, HIV Research and Treatment, and HIV-related health complications and treatments.
h-index
29
citations
3,303
works
157
NIH funding
primary concept
Medicine
email

Recent publications

Living in the shadows: the persistence of secrecy in young people living with HIV on antiretroviral therapy, a qualitative study of the BREATHER Plus trial
SSM - Qualitative Research in Health 2025cited by 1position: middledoi
Sustained aviremia despite anti-retroviral therapy non-adherence in male children after in utero HIV transmission
Nature Medicine 2024cited by 18position: middledoi
D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15 years
Contemporary Clinical Trials 2024cited by 9position: middledoi
Analytical treatment interruption in children living with HIV: position statement from the EPIICAL consortium
The Lancet HIV 2024cited by 6position: middledoi
Long-acting antiretrovirals and HIV treatment adherence
The Lancet HIV 2023cited by 113position: middledoi
Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages
Scientific Reports 2023cited by 48position: middledoi
Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial
The Lancet Child & Adolescent Health 2023cited by 8position: middledoi
Systematic Review of mHealth Interventions for Adolescent and Young Adult HIV Prevention and the Adolescent HIV Continuum of Care in Low to Middle Income Countries
AIDS and Behavior 2022cited by 73position: middledoi
Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial
The Lancet HIV 2022cited by 66position: middledoi
Advancing the prevention and treatment of HIV in children: priorities for research and development
The Lancet HIV 2022cited by 33position: middledoi
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial
The Lancet HIV 2022cited by 29position: middledoi
“I am not shy anymore”: A qualitative study of the role of an interactive mHealth intervention on sexual health knowledge, attitudes, and behaviors of South African adolescents with perinatal HIV
Reproductive Health 2022cited by 27position: middledoi
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial
The Lancet HIV 2022cited by 23position: middledoi
COVID-19 and HIV viral load suppression in children and adolescents in Durban, South Africa
Southern African Journal of HIV Medicine 2022cited by 12position: lastdoi
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children
UCL Discovery (University College London) 2021cited by 103position: middle
HIV status alters disease severity and immune cell responses in Beta variant SARS-CoV-2 infection wave
eLife 2021cited by 49position: middledoi
Similar Antibody Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 in Individuals Living Without and With Human Immunodeficiency Virus on Antiretroviral Therapy During the First South African Infection Wave
Clinical Infectious Diseases 2021cited by 44position: middledoi
ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing
BMC Infectious Diseases 2021cited by 40position: middledoi
‘It was not okay because you leave your friends behind’: A prospective analysis of transition to adult care for adolescents living with perinatally-acquired HIV in South Africa
Vulnerable Children and Youth Studies 2021cited by 33position: middledoi
Development and validation of the HIV adolescent readiness for transition scale (HARTS) in South Africa
Journal of the International AIDS Society 2021cited by 25position: middledoi
Transition from pediatric to adult care for adolescents living with HIV in South Africa: A natural experiment and survival analysis
PLoS ONE 2020cited by 47position: middledoi
HIGH-FREQUENCY failure of combination antiretroviral therapy in paediatric HIV infection is associated with unmet maternal needs causing maternal NON-ADHERENCE
EClinicalMedicine 2020cited by 41position: middledoi
Disclosure, Social Support, and Mental Health are Modifiable Factors Affecting Engagement in Care of Perinatally-HIV Infected Adolescents: A Qualitative Dyadic Analysis
AIDS and Behavior 2020cited by 35position: middledoi
Sex-specific innate immune selection of HIV-1 in utero is associated with increased female susceptibility to infection
Nature Communications 2020cited by 27position: middledoi
Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list
The Lancet HIV 2019cited by 61position: middledoi
Malnutrition in HIV-Infected Children Is an Indicator of Severe Disease with an Impaired Response to Antiretroviral Therapy
AIDS Research and Human Retroviruses 2017cited by 59position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

Jessica E. Haberer · Harvard University Press6 papers (2020–2022)Thobekile Sibaya · Children's Healthcare of Atlanta6 papers (2017–2022)Brian C. Zanoni · Emory University6 papers (2020–2022)Madeleine Goldstein · Emory University2 papers (2022–2022)Nicholas Musinguzi · San Francisco General Hospital2 papers (2020–2021) · 2 papers (2020–2021)Tim R. Cressey · ChiangRai Prachanukroh Hospital2 papers (2021–2022)Christina Psaros · Harvard University2 papers (2020–2021)Natella Rakhmanina · George Washington University1 papers (2022–2022)Lynne Mofenson · Elizabeth Glaser Pediatric AIDS Foundation1 papers (2023–2023)Magdalena E. Sobieszczyk · NewYork–Presbyterian Hospital1 papers (2017–2017)Abbas Lugemwa · University of Padua1 papers (2021–2021)Eric Decloedt · Stellenbosch University1 papers (2023–2023)Andreas Groll · Ludwig-Maximilians-Universität München1 papers (2017–2017)Henrik N. Kløverpris · LEO Foundation1 papers (2017–2017)Deborah Ford · University of Padua1 papers (2021–2021) · 1 papers (2017–2017) · 1 papers (2025–2025) · 1 papers (2025–2025)Mark F. Cotton · Stellenbosch University1 papers (2021–2021)